Brii Biosciences Limited (BRII-B) reported several capital movements between 10 and 24 August 2026 that marginally expanded its share base while strengthening its treasury stock position.
The company issued 255,793 new ordinary shares—equivalent to 0.04 % of the 721.98 million shares outstanding at end-July—through four employee-incentive transactions: • 12,000 shares (0.0017 %) were allotted on 10 August upon exercise of options under the 2023 Share Option Scheme at HKD 0.964 per share. • 102,000 shares (0.0141 %) were issued on 11 August from the 2018 pre-IPO incentive plan at USD 0.05 per share. • Two tranches of restricted share unit (RSU) vesting under the 2021 Post-IPO Share Award Scheme delivered 37,190 shares on 17 August and 104,603 shares on 24 August, both at nil consideration.
On 24 August, the company repurchased 60,000 shares on the Hong Kong Stock Exchange at prices ranging between HKD 0.995 and HKD 1.01, for a total outlay of HKD 0.06 million. The entire repurchased amount has been retained as treasury shares, invoking a 30-day moratorium on new share issues or treasury share sales until 23 September 2026.
Net of the buy-back, the company’s shares in issue (excluding treasury shares) rose by 195,793 to 722.17 million, while treasury shares increased to 12.78 million. Aggregate issued share capital—including treasury stock—stands at 734.96 million shares as of 24 August 2026.
The repurchase utilised 0.008 % of the 72.19 million-share mandate approved on 16 June 2026, leaving substantial capacity for further market purchases should management deem them appropriate.
Comments